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Abstract In 1995 Benington and Heller formulated an
energy hypothesis of sleep centered on a key role of
glycogen. It was postulated that a major function of
sleep is to replenish glycogen stores in the brain that
have been depleted during wakefulness which is associ-
ated to an increased energy demand. Astrocytic glyco-
gen depletion participates to an increase of extracellular
adenosine release which influences sleep homeostasis.
Here, we will review some evidence obtained by studies
addressing the question of a key role played by glyco-
gen metabolism in sleep regulation as proposed by this
hypothesis or by an alternative hypothesis named
“glycogenetic” hypothesis as well as the importance of
the confounding effect of glucocorticoïds. Even though
actual collected data argue in favor of a role of sleep in
brain energy balance-homeostasis, they do not support a
critical and direct involvement of glycogen metabolism
on sleep regulation. For instance, glycogen levels during
the sleep-wake cycle are driven by different physiological
signals and therefore appear more as a marker-integrator of
brain energy status than a direct regulator of sleep homeo-
stasis. In support of this we provide evidence that blockade
of glycogen mobilization does not induce more sleep
episodes during the active period while locomotor activity
is reduced. These observations do not invalidate the energy
hypothesis of sleep but indicate that underlying cellular
mechanisms are more complex than postulated by
Benington and Heller.
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While sleep has been investigated over decades, the funda-
mental question of why we need to sleep is still unanswered.
More specifically, the physiological function(s) fulfilled by
sleep remain(s) elusive. Among the formulated hypotheses is
the necessity of sleep to reestablish brain energy stores that are
altered during wakefulness. The main postulate behind this
theory is that energy stores are diminished during the meta-
bolically active waking period and need to be restored during
sleep. Based on this, Benington and Heller formulated almost
20 years ago an energy hypothesis of sleep proposing glyco-
gen and adenosine (Ade) as key regulators of sleep homeo-
stasis (Benington and Heller 1995). This model suggests that
glycogen stores depletion occurs during waking leading to
Ade formation in the extracellular space, which in turn acts as
a promoting agent of sleepiness influencing sleep homeosta-
sis. As glycogen is exclusively found in astrocytes, a glial cell
type, in the central nervous system (CNS), this points to a
major role of astrocyte functions (in particular with regard to
brain energy homeostasis) in sleep regulation.
Since the formulation of Benington and Heller hypothesis,
numerous studies have been undertaken to validate, or not, the
importance of glycogen store depletion and replenishment as a
key regulator of sleep. This review will first introduce basic
concepts of brain glycogen metabolism and of the structure
and regulation of sleep. Then, major findings related to the
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involvement of glycogen in sleep will be discussed, focusing
on:
a) Benington and Heller hypothesis (BHH)
b) “Glycogenetic” hypothesis
c) A synthesis of experimental data
d) Effect of direct modulation of glycogen levels on sleep
e) Confounding effects of glucocorticoïds (GCs)
Brain glycogen metabolism
The precise functions of brain glycogen are still not fully
characterized. Nevertheless, it has been shown that glycogen
reserves are consumed during failure of energy supply and
strong evidence suggests that glycogen mobilization is tightly
coupled to neuronal activity and could provide additional
energy substrates for neurones during period of activity. For
instance, glycogen accumulation is observed in conditions of
decreased neuronal activity such as phenobarbital anaesthesia
(Phelps 1972), hibernation (Swanson 1992) or during slow
wave sleep (SWS) (Karnovsky et al. 1983). In contrast, cere-
bral glycogen breakdown is observed following sensory stim-
ulation (Dienel et al. 2007; Swanson et al. 1992). Moreover,
the greatest accumulation of glycogen has been reported in
areas of high synaptic density (Koizumi and Shiraishi 1970;
Koizumi and Shiraishi 1971; Phelps 1972), further supporting
the idea that glycogen may be involved in neuronal activity.
Experiments also demonstrated that glycogen is mobilized to
support energy needs of axons upon action potential propaga-
tion in an optic nerve preparation (Brown et al. 2003; Brown
et al. 2004).
Most of our knowledge about glycogen metabolism origi-
nates from studies conducted in peripheral tissues but are
common for all tissues (see e.g. Bollen et al. 1998; Jensen
and Richter 2012; Roach et al. 2012) (Fig. 1a). Uridine di-
phosphate glucose (UDP-glucose) is the source of all glucosyl
residues added to glycogen. UDP-glucose is formed from the
conversion of glucose-6-phosphate to glucose-1-phosphate by
phosphoglucomutase. The first step in the biogenesis of gly-
cogen is the autocatalytic attachment of glucosyl units to a
single tyrosine residue of glycogenin. Elongation of this
“primed” glycogenin is performed by the concerted action of
glycogen synthase (GS) and branching enzyme. Glycogen
synthase elongates the glycogen chain whereas branching
enzyme produces new branches, creating a mature glycogen
granule. In contrast to glycogen synthesis, glycogenolysis is a
process that does not require energy. It is not a reverse reaction
of glycogen synthesis, but implies the concerted action of
glycogen phosphorylase (GP) and the bi-functional
debranching enzyme releasing glucose residue of glycogen
granules as glucose-1-phosphate. Finally, glucose-1-
phosphate is converted by phosphoglucomutase to glucose-
6-phosphate which is (in the brain) the final product of glyco-
gen degradation. Glucose-6-phosphate can then re-enter gly-
colysis or the pentose phosphate pathway (Fig. 1a).
Glycogen is a highly dynamic pool of glucose, the metab-
olism of which is under complex regulation involving various
allosteric factors as well as covalent modifications and com-
partmentalization of key enzymes (for reviews see Bollen
et al. 1998; Brown 2004). In general, activation of glycogen
synthesis results in the inhibition of the degradative pathway,
and vice versa. Glycogen synthase and GP represent two
central elements of this regulation. Glycogen synthase is
tightly controlled by the reversible phosphorylation of multi-
ple serine residues by various protein kinases. Generally,
phosphorylation is associated with an inactivation of the en-
zyme (conversion of the active a-form to the b-form). Like
GS, GP is regulated by phosphorylation. Glycogen phosphor-
ylase is converted from the inactive b-form to the active a-
form through phosphorylation by phosphorylase kinase. As
described, kinase-catalyzed phosphorylation of both enzymes
leads to glycogenolysis (by activation of GP and inactivation
of GS) whereas dephosphorylation favors glycogenesis.
Protein phosphatase-1 (PP-1) is the enzyme responsible for
dephosphorylation of both GS and GP (Newgard et al. 2000).
In order to be active, PP-1 must be bound to glycogen. This is
accomplished by specific glycogen-binding G-subunits,
Fig. 1 Gylcogenmetabolism in astrocytes. a Schematic representation of
glucose metabolism. Glucose enters cells trough glucose transporters
(GLUT) and is phosphorylated by hexokinase (HK) to produce
glucose-6-phosphate. Glucose 6-phosphate can be processed into
different metabolic pathways. It can be metabolized through the pentose
phosphate pathway (PPP) or through glycolysis giving rise to pyruvate
production. Pyruvate can enter mitochodria where it is metabolized
through the Krebs cycle and oxidative phosphorylation. Alternatively,
pyruvate can be reduced to lactate by lactate dehydrogenase (LDH) and
be released in the extracellular space through monocarboxylate
transporters (MCT). Glucose-6-phosphate can also be used to store
glucosyl units as glycogen. As a first step glucose-6-phosphate is
converted to UDP-glucose through the action of phosphoglucomutase
(PGM) and UDP-glucose pyrophosphorylase (UDPGP). UDP-glucose is
then incorporated into glycogen by glycogen synthase (GS). Protein
targeting to glycogen (PTG) is a specific glycogen-binding G-subunit,
which is responsible for the targeting of protein phosphatase 1 to
glycogen. Through this action, PTG promotes GS dephosphorylation
and activation therefore favouring glycogen synthesis. In case of energy
needs, glycogen can be broken down by glycogen phosphorylase (GP) to
produce glucose-1-phosphate that is converted back to glucose-6-
phosphate through the action of PGM. Adapted from (Allaman 2009)
with permission. b Differential modulation of glycogen metabolism in
cultured astrocytes by noradrenaline (NA). Activation of cAMP-
dependent intracellular signalling by NA results in a short term
(seconds to minutes, in green) glycogenolysis and in a delayed (hours,
in red) glycogen resynthesis. This long-term response requires induction
of gene expression and is accompanied by stimulation of mRNA
expression of protein targeting to glycogen (PTG), a member of the
glycogen-targeting subunits of protein phosphatase 1, and by the
activation of glycogen synthase (see text for details). Adapted from
(Magistretti 2006) with permission
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which are responsible for targeting PP-1 to glycogen. Among
them, two are expressed in the brain: the human PPP1R3C
(and its mouse homologue Protein Targeting to Glycogen,
PTG) (Doherty et al. 1996; Printen et al. 1997) and PPP1R6
(Armstrong et al. 1997). In addition to its capacity to target
PP-1 to glycogen, PTG is also able to bind several of the
enzymes involved in glycogen metabolism including GS, GP
a-form and phosphorylase kinase (Brady et al. 1997; Printen
et al. 1997). Based on these observations, it has been sug-
gested that PTG could act as a molecular scaffold protein
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assembling the different enzymes necessary for glycogen
metabolism (Brady et al. 1997; Mastick et al. 1998).
At the cellular level, glycogen is mainly located in astro-
cytes in the CNS (Brown 2004; Cataldo and Broadwell 1986;
Magistretti et al. 1993). The cellular localization of GS and GP
correlates with the presence of glycogen. Both brain and
muscle isozymes of GP are located predominantly in astro-
cytes (Ignacio et al. 1990; Pfeiffer-Guglielmi et al. 2003).
As in peripheral organs, brain glycogen levels are also
under the tight control of numerous neuro-humoral factors.
Thus, insulin and insulin-like growth factor I increase glyco-
gen content of astrocytes in culture (Dringen and Hamprecht
1992; Hamai et al. 1999). Moreover, various neuroactive
substances possess glycogenolytic properties in vitro (for
review see Magistretti et al. 1993). In particular, a glycogen-
olytic effect of potassium, vasoactive intestinal peptide (VIP),
Ade and noradrenaline (NA) have been demonstrated in
mouse cerebral cortical slices as well as in primary cultures
of cortical astrocytes (Hof et al. 1988; Magistretti et al. 1981;
Quach et al. 1978; Sorg and Magistretti 1991).
In addition to their rapid glycogenolytic effect, NA, VIP
and Ade lead to massive glycogen resynthesis in cultured
astrocytes, which takes place over several hours (Allaman
et al. 2003; Sorg and Magistretti 1992). It was determined
that this long-term dynamic regulation of glycogen in astro-
cytes requires an activation of transcription and the synthesis
of new protein(s). This process is mediated by cAMP-
dependent mechanisms, involves the family of transcription
factors CCAAT/enhancer binding protein (C/EBP) and results
in the induction of PTG expression and of GS activity
(Allaman et al. 2000; Cardinaux and Magistretti 1996; Sorg
and Magistretti 1992) (Fig. 1b). Interestingly, overexpression
of PTG in CHO cells (Printen et al. 1997), in cultured rat
hepatocytes (Berman et al. 1998) or in cultured mouse cortical
astrocytes (unpublished data) leads to an increase in basal
glycogen levels without the need of other stimuli. It was
further suggested that increased expression of PTG might
maintain the cell in a glycogenic mode (Berman et al. 1998).
This set of observations finally suggests that in astrocytes, the
induction of PTG alone might be sufficient to account for the
massive glycogen resynthesis triggered by neuromodulators
such as NA, VIP or Ade.
Structure and regulation of sleep
Behavioral and neuronal correlates of sleep including loco-
motor inactivity, specific body posture, high threshold of
sensory reactivity and decrease in global neuronal firing rate,
are shared by numerous animal species from insects to mam-
mals (Campbell and Tobler 1984). This has justified the use of
drosophila and zebrafish as well as rodents as experimental
models in sleep studies (Cirelli and Tononi 2008; Zimmerman
et al. 2008). Using parallel recordings of electroencephalo-
gram (EEG) and electromyogram (EMG), sleep in mammals
and birds can be divided in two main stages: SlowWave Sleep
(SWS) also called Non-Rapid Eye Movement (NREM) sleep
and Paradoxical Sleep (PS) equivalent to Rapid Eye Move-
ment (REM) sleep. The three vigilance states (i.e. waking
(W), SWS and PS) also display major differences in spectral
components of their EEG (Fig. 2). The EEG of SWS is
characterized by oscillations of high amplitude and low fre-
quencies. Power spectrum analysis of this EEG indicates a
large predominance of low frequencies, including sleep spin-
dles (8–14 Hz), delta waves (1–4.5 Hz, also defined as Slow
Wave Activity (SWA)) and slow waves (<1 Hz), correspond-
ing to a high level of synchronization of cortical cells dis-
charge. More precisely, slow waves oscillations are composed
by the alternation of synchronized cell firing periods (UP
states) and silent periods (DOWN states) (Fig. 2b). While
the muscle tone is lower in PS than during waking, the EEG
signal is apparently close to the waking one. EEG displays
oscillations of low amplitude and high frequencies. Power
spectrum of the PS EEG is shifted towards more rapid fre-
quencies with a specific peak at 5-7 Hz (theta band). This peak
is mainly due to the firing rate rhythm of hippocampal neurons
and is particularly apparent in rodents where hippocampus
occupies a dorsal location. During waking, oscillations of low
amplitude and rapid frequencies which correspond to
desynchronization of cortical cells firing, are observed on
the EEG. Depending animal behavior, EEG power spectrum
during waking displays a relative increase in alpha (9-12 Hz),
beta (12-30 Hz) and gamma (>30 Hz) frequency bands.
Alternation of SWS and PS (usually ended by a brief
awakening) constitutes a sleep cycle whose duration is spe-
cific of each animal species. Moreover, in several mammals
such as human, SWS can be subdivided in light-SWS and
deep-SWS. Mammals display a great diversity in their total
sleep time per day as well as in the PS quantity (Siegel 2001).
For example, the big brown bat sleeps almost 20 h/day with
4 h in PS while a horse sleeps about 3 h/day with 0.5 h in PS.
Such a difference in time spent asleep has been initially found
positively correlated to metabolic rate and negatively corre-
lated to brain size (Zepelin and Rechtschaffen 1974). Howev-
er, more precise analysis found that sleep amount better re-
flects ecological constraints in term of foraging or risk of
predation (Capellini et al. 2008). The daily sleep distribution,
which also varies greatly across mammals, is likely also under
the same ecological pressure and remains a major difference
between man and other mammals classically used (rodents) in
sleep research.
The regulation of sleep, although not totally understood,
can be considered as the interaction between circadian clock
and homeostatic mechanisms (Borbely and Achermann
1999). The molecular components (i.e. proteins) of circadian
clock are present in each cell where their cyclic expressions
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are regulated by successive positive and negative transcrip-
tional feedback loops (see Ko and Takahashi 2006; Panda
et al. 2002). These cellular clocks are synchronized by the
central clock of the body localized in the suprachiasmatic
nucleus (SCN), a hypothalamic small nucleus situated just
above the optic chiasma from which it directly receives inputs
encoding light information (Dibner et al. 2010). In basal
conditions, sleep periods occur with a circadian rhythmic
pattern which is abolished when SCN is destroyed (for review
see Moore 2007). Moreover, in humans and mice, polymor-
phisms for clock genes are correlated to different sleep-wake
cycle disturbances such as the familial advanced sleep-phase
syndrome (Per2 mutation) or familial delayed sleep phase
syndrome (Per3 mutations) (Archer et al. 2010; Chong et al.
2012).
Sleep is also regulated via homeostatic mechanisms. In-
deed, total sleep length increases following prolonged wake-
fulness; a phenomenon also called “sleep rebound”. More-
over, during SWS, an increase in SWA (Fig. 2a), correspond-
ing to the power spectrum of the EEG delta band, is observed
during the first hours of the recovery period subsequent to
sleep loss. This SWA increase is generally considered as the
most reproducible index of the homeostatic sleep regulation
(Borbely et al. 1981; Borbely et al. 1984). Interestingly, PS
also displays a homeostatic regulation which seems to be only
reflected by an increase in length of its epochs without major
change in the EEG power spectrum. During the last decade,
experimental data in human and rodents showed that, during
SWS, the SWA is greater in cortical areas which were more
activated during the previous wakefulness period even in
absence of sleep loss (Huber et al. 2004; Vyazovskiy et al.
2000). More recently, using intra-cortical recordings,
Vyazovskiy and coworkers reported that electrophysiolog-
ical features of the SWS (e.g. slow waves between 0.1-
1 Hz) are also expressed by an increasing number of
neurons in parallel to the waking duration (Vyazovskiy
et al. 2011). These results indicate that the homeostatic
regulation of SWA is a “local and use-dependent” phe-
nomenon and challenge the classical view of sleep as the
result of interactions between distributed excitatory and
inhibitory neuronal networks (mainly in diencephalon and
in rhombencephalon) (Krueger and Tononi 2011;
Rattenborg et al. 2012).
Benington and Heller hypothesis (BHH)
Sleep as a state of brain energy conservation
Although the energy cost of each sleep state at cellular or sub-
cellular levels (synapses) is not known, the cerebral variations
of the energy consumption evaluated by glucose uptake mea-
surements performed in human (Buchsbaum et al. 1989; Heiss
et al. 1985; Nofzinger et al. 2002), monkey (Kennedy et al.
1982), cat (Ramm and Frost 1986) and rodents (Jay et al.
1985; Vyazovskiy et al. 2008) clearly indicate that SWS is an
SWA (1-4.5Hz)
UP DOWN
Fig. 2 Sleep architecture. a Twenty four hour EEG power spectra in
NREM sleep (SWS), REM sleep (PS) and waking in one representative
adult male rat (Wistar Kyoto strain). SlowWave Activity (SWA) frequen-
cy spectrum (1–4.5 Hz) is highlighted in grey. b EEG signals and
corresponding cortical multiunit activity (raster plots below; each bar is
a spike) representative of the three vigilance states. Note the fast irregular
pattern of cortical firing in waking and REM sleep, and regular occur-
rence of generalized neuronal silence, corresponding to EEG slowwaves,
in NREM sleep. UP (red) and DOWN (blue) states during NREM sleep
are highlighted. Adapted from (Vyazovskiy and Faraguna 2014) with
permission
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energy sparing stage relative to waking and PS.Measurements
of regional cerebral blood flow (Braun et al. 1997; Madsen
et al. 1991) and metabolic rate (Katayose et al. 2009) during
sleep in human corroborate these results. These data led to
hypothesize that one of the functions of sleep is to preserve
brain energy levels, a fact that could be used to support the
cellular mechanisms related to brain plasticity, especially
those involved in off-line memory processes during sleep
(Tononi and Cirelli 2006).
Sleep and glycogen
In a pioneering study, Karadzic and Mrsulja in 1969 showed
that 72 h of selective PS deprivation, in rats induce changes in
glycogen content in different brain areas (Karadzic and
Mrsulja 1969). These results therefore suggested a direct link
between specific vigilance state (PS) and brain glycogen
content.
Glycogen is classically thought to supplement glucose
uptake by brain during physiological stimulation. A de-
crease in glycogen levels was observed in primary sensory
cortical areas following sensory stimulation (Dienel and
Cruz 2004; Swanson et al. 1992) and histochemistry of
the GP (active a-form) has been used as metabolic marker
of neuronal activation (Harley and Bielajew 1992; Woolf
et al. 1985).
The BHH
Consistent with this view, Karnovsky and co-workers con-
ducted a pivotal study where theymeasured glycogen levels in
rat brain following different times spent awake or different
times spent asleep (Karnovsky et al. 1983). Their results
showed that glycogen levels were greatly increased (+70 %)
during the first 15 min of a sleep period whereas they decrease
more slowly (−30 %) 20 min following an awakening. For
instance, in vitro data indicate that neurotransmitters known to
be specifically released during waking such as NA, serotonin
and histamine (reviewed in Jones 2005), induce a rapid gly-
cogenolysis (Magistretti et al. 1993; Quach et al. 1978; Sorg
and Magistretti 1991). In addition, brain glycogen levels are
lower in the first half of the dark period, when the activity of
mice is maximal, and are higher during the rest period (Hutch-
ins and Rogers 1970). Therefore, during activity period, re-
petitive glycogen degradation should occur in response to the
different behavioral sequences and then, lead to a global
glycogen depletion at the cortical levels. Because glycogen
depletion should correspond to a decrease in ATP/AMP ratio,
Ade levels should increase resulting of 5′-AMP degradation
by ectonucleotidases. Ade could act on different types of
receptors (mainly A1 and A2A, A2B) present on neuronal
cells. A1 receptor stimulation inhibits synaptic transmission
through an increase in K+conductance (gK+) whereas A2A
receptor stimulation activates adenylyl cyclase and exhibits
more vasodilatation and metabolic effects (for review see
Sheth et al. 2014).
In summary, Benington and Heller’s hypothesis (BHH)
proposed that in response to local increase in neuronal
activity, the depletion of glycogen during waking induces
a decrease in the ATP/AMP ratio resulting in accumulation
of extracellular Ade. Extracellular Ade decreases the neu-
ronal firing rate through its action on A1 receptor. Finally,
the inhibitory action of Ade triggers sleep. Sleep, in turn,
allows replenishing glycogen stores which create the ben-
eficial energetic conditions for subsequent waking period
(Fig. 3).
As a direct correlate of BHH, prolonged wakefulness
should induce more profound glycogen depletion compared
to undisturbed animals. Therefore, in order to obtain a direct
demonstration of BHH different research groups assessed
glycogen levels following acute total sleep deprivation (SD)
in various species. One should note that the SD method used
in the subsequent described studies, if not otherwise specified,
is the so-called “gentle” sleep deprivation method. This SD
method consists on gently modifying the animal environment
(i.e. changing a part of its bedding material, introducing new
object into the cage) when animal presents behavioral signs of
sleepiness (i.e. prolonged immobility or adopting sleep
posture).
Testing the BHH
A first set of experiments was conducted by Heller’s group in
which glycogen levels were measured in different brain re-
gions following 6 h and 12 h periods of SD in young rats (Gip
et al. 2002). In this study, animals were sacrificed using
microwave irradiation (Gip et al. 2002) to preserve glycogen
from rapid degradation as induced by killing animals by
decapitation. Indeed, this method of sacrifice represents the
best available method to measure true physiological concen-
trations of energy metabolites such as glycogen, lactate or
glucose that display very rapid changes when ATP/AMP ratio
falls. Results of this study indicate that cerebellar levels of
glycogen were decreased after 6 h of SD whereas no change
was observed in cerebral cortex. Interestingly, a decrease in
both structures was only observed after 12 h of SD (Gip et al.
2002). Similar results were also obtained by Kong and co-
workers in rats also sacrificed with a microwave irradiator
(Kong et al. 2002). These authors, who measured glycogen
in the whole brain (minus cerebellum and brainstem),
showed that glycogen levels were decreased by 38 % after
12 h of SD.
The BHH has also been assessed in different inbred strains
of mice (C57BL/6j (B6), AKR/j (AK) and DBA/2j (D2)) that
differ in their homeostatic response in SWA to a 6 h of SD
with the most pronounced response in AKmice and the lowest
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in D2 mice (Franken et al. 2003). Increased SWA response is
thought to be correlated with more pronounced neuronal
activity during the previous waking period. According to the
BHH, this should consequently lead a larger glycogen deple-
tion in AK mice than in D2 mice. Similarly to experiments
performed in rats by Heller’s group (see above), Franken and
co-workers sacrificed the mice after 6 h of SD by microwave
irradiation and measured glycogen levels in the cerebral cor-
tex, the brainstem and the cerebellum. The main results of this
study indicate that glycogen levels increased by 40 % in the
cortex of B6 mice whereas they remained unchanged in AK
andD2mice (Fig. 4). A straightforward conclusion from these
observations is that mice that differ the most in their SWA
response to SD did not exhibit differences in their glycogen
levels. This absence of correlation therefore does not support
BHH and suggests that factors other than homeostatic re-
sponse in SWA may underlie strain differences in term of
glycogen response to SD. For instance, it was proposed by
the authors that differences in stress responses may govern
such metabolic response (see below). In addition to this, these
studies demonstrated that cerebral glycogen regulation dis-
plays some specific variations which depend on the brain
region studied. Indeed, in contrast to what was found at the
cortical level, glycogen levels decreased by 20-38 % in
brainstem and cerebellum in AK and D2 mice though no
change was observed in B6 mice (Fig. 4).
Impact of SD on brain glycogen levels has also been
evaluated in the fruitfly (Drosophila melanogaster)
(Zimmerman et al. 2004). In these experiments, Zimmerman
and collaborators measured glycogen levels following 3 h or
6 h of rest deprivation (RD) (Zimmerman et al. 2004).While a
decrease was observed in the whole head and body, 6 h of RD
failed to induce a significant decrease in glycogen levels in the
brain. Unexpectedly, it was also observed that brain glycogen
levels decreased after a shorter RD (3 h).
As a whole, these observations pinpoint the absence of
glycogen depletion in the cortex following a 6 h period of
SD (as observed in rats, mice and drosophila) and therefore
failed to validate BHH.
The “glycogenetic” hypothesis
Setting the context
Based on BHH, Magistretti and Borbèly later on proposed an
alternative hypothesis linking sleep and glycogen metabolism
in the brain, that we will call the “glycogenetic” hypothesis.
This hypothesis is essentially based on in vitro results obtain-
ed in Magistretti’s laboratory on glycogen metabolism regu-
lation using primary culture of astrocytes from postnatal mice.
As opposed to BHH which only considers short term glyco-
genolysis effects (in minutes) induced by the neurotransmit-
ters released during waking, the “glycogenetic” hypothesis
relies on the observations that some of these same neurotrans-
mitters (NA, VIP, Ade) also trigger long-term glycogen re-
synthesis (in hours) (Sorg and Magistretti 1992) (see above
and Fig. 1b). As previously mentioned, this resynthesis in-
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Magistretti 1996) as well as transcription and translation of
proteins involved in glycogen synthesis such as PTG which
set glycogen in a synthetic mode (Allaman et al. 2000;
Allaman et al. 2003; Berman et al. 1998; Printen et al.
1997). Hence, at the beginning of the waking period, one
can postulate that release of these aforementioned neurotrans-
mitters induces a net consumption of glycogen but, in parallel,
also triggers a “glycogenetic program” leading to a delayed
resynthesis of glycogen that will occur during wakefulness.
As a matter of fact, such a “rebound” in glycogen levels was
also observed in vivo after a single hypoglycemic episode
(Choi et al. 2003) and in mice injected with amphetamine
(Hutchins and Rogers 1970). Such glycogen regulation is also
consistent with the observations made by Hutchins and
Rogers (1970) which indicate that, while brain glycogen
levels are low at the beginning of the active period, they
increase before the end of this period (see Fig. 3 in Hutchins
and Rogers 1970).
The “glycogenetic” hypothesis
Actually, this alternative to BHH proposed that during wake-
fulness, in addition to their glycogenolytic effects, NA, VIP
and Ade also trigger glycogen synthesis through transcription-
al and translational effects. Therefore, glycogen levels should
be maintained and even increased at the end of the wakeful-
ness period (Fig. 3). Since the mechanisms which underlie this
assumption have been obtained from cortical cells and since
EEG signal reflected cortical activity pattern, the cerebral
cortex was mainly considered as “the site” for “glycogenetic”
hypothesis. In addition, as a consequence of the
“glycogenetic” hypothesis and in contrast to the BHH we also
proposed that glycogen preservation could have a role in the
triggering of sleep and/or more particularly, in the occurrence
and/or length of the PS episodes. As a matter of fact, PS is an
energy consuming state that occurs following SWS episodes
in which glucose consumption is low in the cortex. Thus,
glycogen preserved during waking could be the cellular
source of glucose required to ensure the neuro-metabolic
coupling in response to increased neuronal activity during
PS episodes (Fig. 3).
Testing the “glycogenetic” hypothesis
In order to test this hypothesis, we first assessed the expression
in the cerebral cortex of important genes encoding proteins
related to glycogen metabolism such as GS, GP and PTG at
four time points across the sleep-wake cycle as well as the GS
activity following 6 h of SD in OF1 mice (Petit et al. 2002).
Contrary to what was postulated, it was first observed that GS
and GP mRNA levels were minimum during the active period
and maximum during the rest period and that both decreased
after 6 h of SD. However, PTG mRNA levels reached a
maximum at the end of the active period and were markedly
induced by SD (+94 % vs control value). Since PTG mRNA
induction is known to promote GS activity and glycogen
synthesis, one can logically deduce that a similar mechanism
is engaged by 6 h of SD. Consistent with this, it was demon-
strated that the active form of GS was significantly increased
following SD in the cortex whereas the total form of GS (a+b
forms) remained unchanged. Moreover, if ones assume that
such a glycogenetic mode is taking place at the cortical levels
this could provide an explanation for the absence of glycogen
depletion at the cortical level following 6 h of SD as described
in several studies (see above) (Franken et al. 2003; Gip et al.
2002; Zimmerman et al. 2004).
Even though the “gentle” SD method used in the previous-
ly described reports avoids stressful stimulations (acute in-
tense noise or light, water or air puffs), plasma GCs levels are
increased by two to fourfold in such protocols (Gip et al. 2004;
Petit et al. 2010; Tobler et al. 1983).
Fig. 4 Changes in brain glycogen after sleep deprivation vary with
genotype. Brain glycogen content in sleep-deprivedmice. Brain glycogen
varied with strain and structure (2-way ANOVAwith repeated measures
for factor structure. Factor strain, F2,30=13.2, P<0.0001; structure,
F2,60=71.9, P<0.0001; interaction, F4,60=1.6, P=0.20). Bars represent
mean values ±2SE. Top panels: *significant strain differences for each
brain region (Tukey’s range test; P<0.05). Bottom panels: *significant
differences from control (unpaired 2-sided t-tests; P<0.05). In the bottom
panels, values were expressed as % difference from the mean values in
the control group (0 %). CTX, cerebral cortex; BS, brainstem; CB,
cerebellum. Adapted from (Franken et al. 2003) with permission
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In order to establish whether or not these metabolic chang-
es were restricted to the “gentle” SDmethod, we also explored
the impact of a pharmacological SD, which does not require
intervention and therefore limits possible stress confounding
effects. To this end we used modafinil (MOD) which is a non-
amphetamine vigilance–promoting drug classically used in
narcoleptic patients (Wise et al. 2007). In mice, a single
injection of this drug induces a continuous wakefulness during
5–6 h followed by a SWA rebound in the following period
similar to those obtained after gentle SD (Kopp et al. 2002).
Different glycogen metabolism indices including levels of
mRNA encoding GS, GP and PTG as well as glycogen levels
were measured in the cortex of mice. Whatever the method
used for SD (gentle or pharmacological), it was observed that
cortical PTG mRNA levels and GS activity were consistently
increased (Petit et al. 2010). In addition, we showed that
glycogen levels displayed no change in the cortex in both
SD methods used, indicating that glycogen regulation is driv-
en by the prolongation of wakefulness and not by the “gentle
SD” per se. Interestingly, PTG mRNA and glycogen levels
were normalized following 3 h of sleep recovery. Induction of
PTG mRNA levels was also reported in cDNA microarray
analysis performed following SD experiments in mice (Maret
et al. 2007; Mongrain et al. 2010). We should also notice that
an induction of glycogenin, is also regulated by “gentle” SD,
suggesting that de novo granules formation could also partic-
ipate to glycogen regulation after SD (Petit et al. 2010). Along
the same line, a single dose of methylphenidate (Ritalin™)
which is able to maintain B6 mice awake for 3–4 h, also
induced a significant increase in PTG mRNA levels (+50 %)
as well as in glycogenin mRNA (+22%) in the anterior part of
the cortex (unpublished data).
These results argue in favor of a glycogen synthesis occur-
ring during waking in parallel to glycogenolysis induced by
repeated sensory-motor stimulations or pharmacological neu-
ronal stimulations. This is likely achieved by the increase in
PTG levels which is able to direct glycogen metabolism
preferentially towards synthesis.
Cortical glycogen turnover increases during prolonged
wakefulness
One of the limitations of determination of glycogen levels at
the end of a SD, or following sleep recovery, is that it doesn’t
allow the dynamic measurements of glycogen metabolism
during these periods. By measuring the incorporation of
[1-13C]glucose into glycogen by Nuclear Magnetic Reso-
nance (NMR) spectroscopy, Gruetter and co-workers deter-
mined glycogen concentration and turnover in rat brain
in vivo (Choi et al. 1999; Choi and Gruetter 2003; Lei et al.
2007). This method has been used to determine glycogen
concentration and turnover in euglycemic rats maintained
awake during 5 h at the beginning of the rest period, compared
to undisturbed rats (Morgenthaler et al. 2009). Following
normalization by the N-acetyl-aspartate turnover, that remains
constant, it was demonstrated that glycogen cycles faster (2.9
vs 5.3 h, p<0.05) in rats continuously maintained awake by
sensory stimulations during the labeling period, revealing an
increase in glycogen turnover induced during prolonged
wakefulness. In contrast, glycogen concentration remained
unchanged in the same animals (4.0 vs 3.9 μmol/g)
(Morgenthaler et al. 2009). These results are in accordance
with those obtained in rodents and flies following 6 h of SD
andwith our results showing an increase in GS activity in spite
of constant glycogenolysis evoked by prolonged wakefulness
(Petit et al. 2010).
A synthesis of experimental data
Based on these experimental data, we can propose the follow-
ing model of glycogen regulation throughout the sleep-wake
cycle:
– When arousal occurs, the rise in wakefulness-related neuro-
transmitters (monoamines, VIP and Ade) (e.g. see
Takahashi et al. 2010) triggers a rapid (within few minutes)
glycogenolysis throughout the whole cortex. This phase
corresponds to the fall in glycogen concentration after 2–
5 min of spontaneous awakening reported by Karnovsky
and collaborators (Karnovsky et al. 1983). During the wak-
ing period, glycogenolysis is also repeatedly triggered in
specific areas corresponding to sensory modalities solicited
by novel environmental conditions and in motor areas. This
view is in accordance with an important neuromodulatory
role of the cortical projections of the noradrenergic cells
from the locus coeruleus. These cells, in addition to a tonic
mode of discharge during waking, display a phasic firing in
response to salient sensory stimuli (Berridge and
Waterhouse 2003; but see also Foote et al. 1983).
– At the same time, NA (and probably VIP and Ade)
triggers the transcription and translation of PTG leading
to an increase in GS activity.
– Therefore, a balance between synthesis and degradation
progressively settles during the activity period and pre-
vents glycogen decrease. This balance is also dependent
of the stress levels since GCs favor glycogenolysis (see
below). It appears that, this relative “steady state” cannot
be maintained when wakefulness duration is prolonged
more than 6–10 h in rodents as suggested by the results
obtained after 12 h of SD (Gip et al. 2002; Kong et al.
2002).
– When sleep emerges, the inhibition of the sensory inputs
to the cortex together with the decrease in the monoam-
inergic tone, reduces the cortical energy needs and
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consequently decreases glycogen consumption. This rap-
id unbalance in support of glycogen synthesis could
explain the large increase in glycogen levels observed
by Karnovsky and collaborators 15 min after sleep onset
(Karnovsky et al. 1983).
– Finally, PTG levels and glycogen synthesis diminish
during sleep as indicated by glycogen levels mea-
sured following 3 h of sleep recovery (Petit et al.
2010).
Effect of direct modulation of glycogen levels on sleep
Because experimental data support the glycogen maintenance
proposed by the “glycogenetic” hypothesis, we wanted to test
a physiological consequence of this observation which as-
sumes that glycogen levels per se could regulate sleep. To
investigate this aspect we took advantage of pharmacological
agents that block glycogen degradation (Treadway et al.
2001).
1,4-dideoxy-1,4-D-arabinitol (DAB) as pharmacological tool
In order to normalize glycemia, a large number of molecules
inhibiting GP through different binding sites were designed
(Oikonomakos and Somsak 2008). Among them, several
glucose analogs based on iminosugars such as Isofagomine
or DAB act on the active form of GP (GP a-form), the rate-
limiting enzyme of glycogen mobilization, by allosteric inhi-
bition (Somsak et al. 2003). In vitro, DAB potently inhibits
GP in different preparations (Andersen andWestergaard 2002;
Somsak et al. 2003) including brain tissue homogenates
(IC50≈0.4 μM) (Walls et al. 2008). Moreover, DAB is effec-
tive in blocking glycogen mobilization in astrocytes as shown
by the full prevention of NA-induced glycogenolysis by this
compound in astrocytes in culture (Walls et al. 2008). Impor-
tantly, DAB was used to demonstrate the importance of brain
glycogen mobilization for the establishment of memory for-
mation (Gibbs et al. 2006; Newman et al. 2011; Suzuki et al.
2011). The last set of results confirms DAB as a relevant
pharmacological tool to investigate glycogen function
in vivo.
Testing the blockade of glycogen in spontaneous sleep-wake
cycle
In order to assess more directly the role of glycogen on the
sleep-wake architecture and /or on the occurrence and the
duration of PS epochs, we used DAB to block brain glycogen
mobilization in mice housed in basal conditions (light–dark
cycle: 12:12), (Fig. 5). Mice received an intra-cerebro-
ventricular (i.c.v) injection of either saline solution (control)
or DAB (0.5 M). Each injection was performed at the light/
dark shift (i.e. zeitgeber time (ZT) 12) that corresponds to the
beginning of the active period in rodents.
We first verified the GP inhibitor efficiency in vivo by
measuring cortical glycogen levels 3 h after i.c.v injection of
DAB. As expected, glycogen levels were significantly more
elevated (fivefold) in the DAB group as compared to control
group (Fig. 5a).
In a second set of experiments, using a similar protocol, we
assessed a possible effect of glycogen mobilization blockade
on spontaneous locomotor activity (SLA) in mice. Injections
were also performed at ZT12 and SLA was continuously
recorded during 10 h from ZT14 until the end of the dark
period (ZT24). During this period, SLA was significantly
decreased by 38 % in DAB mice as compared to control
(Fig. 5b). This last result suggests that an inhibition of glyco-
genmobilization in the brain might induce an increase of sleep
and/or quiet wake in mice.
To clarify this last point, we repeated the experiment with
mice already implanted with EEG/EMG electrodes and wire-
connected for sleep recordings. DAB or saline were injected
at ZT12 and classical vigilance states parameters were re-
corded over a 10 h period (ZT14-ZT24). Results did not
indicate any significant effect of DAB on SWS nor on PS
parameters during this recording period (Fig. 5c). To investi-
gate whether GP inhibition could alter sleep more qualitative-
ly than quantitatively, we also performed a spectral analysis
of the EEG during SWS epochs (by 2 h bin from ZT14 to ZT
24 in control and DAB-injected mice). For this, we focused
our analysis on the SWA (power spectrum of the delta fre-
quency band) which represents an index of sleep depth. A
slight but non-significant decrease in SWA was observed
following DAB injections indicating that the depth of the
SWS was not altered by the glycogen blockade (data not
shown).
These last results indicate that the large decrease in loco-
motor activity observed after DAB injection is not due to
increase in sleep duration, even though an increase of quiet
wake/drowsiness could not be excluded. This could suggest
that blockade of glycogen mobilization might impact more
specifically brain areas involved in locomotion. Similarly,
intraperitoneal injection of caffeine at a dose (200 mg/kg) that
inhibits GP, also depressed the locomotor activity in mice
(Hutchins and Rogers 1970). Thus, and in contrast to the
“second part” of our hypothesis where we proposed that
maintaining glycogen levels during waking could regulate
sleep, acute blockade of glycogen mobilization by DAB has
no effect on sleep parameters during the subsequent active
period. In particular, our results cast some doubt on the pos-
sibility that glycogen could be used as energy source for PS
episodes since no change in both number or length of PS
epochs was observed. Moreover, our DAB experiments con-
stitute an additional argument that doesn’t support the BHH.
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Indeed, according to this assumption, glycogen mobilization
blockade should create energy deficits more rapidly and,
consequently, should increase length and/or number of sleep
episodes for activity period, a fact that is not verified experi-
mentally (see above).
Based on this study with DAB, sleep occurrence and
duration appear to be relatively independent to brain glycogen
content, at least on a relative short period (about 10–12 h) and
in standard environment.
However, it cannot be excluded from this study that gly-
cogen mobilization blockade affects other cellular processes
in sub-cortical structures such as hippocampus where memory
mechanisms occur (for example the sharp waves ripples)
during sleep stages (for review see Rasch and Born 2013).
Confounding effect of GCs
GCs affect cerebral metabolism
GCs are adrenal steroid hormones released in response to
stressors. As previously mentioned, stress is a possible con-
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Fig. 5 Effects of acute pharmacological inhibition of glycogen mobili-
zation on locomotor activity and sleep parameters when added at dark
onset. Experiments were performed on adult males mice (C57BL/6j from
Janvier, France) equipped with EEG and EMG electrodes (for further
details see Petit et al. 2013) and implanted with a chronic cannula into the
lateral ventricle. The mice were housed individually under a 12-h:12-h
light–dark cycle at 23 °C ambient temperature with food and water ad
libitum. Twoweeks after the surgery, they were injectedwith 2μl of NaCl
0.9 % (control [CTL] group, white bars) or 1,4-dideoxy-1,4-imino-D-
arabinitol (DAB) at 0.5 M dissolved in NaCl 0.9 % (DAB group, gray
bars) at the beginning of the dark period (Zeitgeber Time 12, ZT12) under
a light isoflurane anesthesia. After injections, mice were let 2 h in their
cages for anesthesia recovery before recordings begin. a Brain glycogen
levels 3 h after i.c.v. administration of DAB. After the injection, the
animals were replaced in their cages and sacrificed 3 h later (ZT15).
The brains were quickly removed, frozen and cut for site injection
verification and standard glycogen dosage (Petit et al. 2010). The values
represent the mean of glycogen levels in nmol/mg prot (±SEM) measured
on brain slices from -200 μm posterior to +200 μm anterior compared to
the injection site in both group (CTL vs DAB). N=6. Statistics: Unpaired
t test with Welch’s correction,**** p value <0.0001 compared to CTL. b
Spontaneous Locomotor Activity (SLA) after i.c.v injection of DAB.
Each cage was equipped with passive infrared sensors on the top for
SLA recordings. SLAwas recorded for 10-min interval during 10 h from
ZT14 to ZT24. The same animals received NaCl 0.9 % and DAB on
separate days. The values represent mean SLA ± SEM over this 10 h
period in both group (CTL vs DAB). N=12. Statistics: Paired t test, *** p
value=0.0004 compared to CTL. c Quantitative parameters of the sleep
wake cycle after i.c.v. injection of DAB. The EEG/EMG signals were
recorded and digitalized with an Embla A10 amplifier (Medcare, USA).
The EEG was divided in 4-s epochs which were visually scored in one of
the three states of vigilance (wakefulness (W), slow wave sleep (SWS) or
paradoxical sleep (PS)) according to classical criteria (Tobler et al. 1997).
Values represent the mean values (±SEM) of cumulative duration (min),
number of episodes and episode mean duration (min) for each state of
vigilance for the 10 h of recording session from ZT14 to ZT24. N=6
animals in each group. Statistics: One way ANOVA followed by
Bonferroni’s post-test. No statistical difference was observed between
the control and the DAB groups
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(which can result in an increase of plasma corticosterone, a
physiological stress marker in rodents i.e. the main GCs in rat
and mice).
An important role of GC in peripheral tissues is the regu-
lation of glucose homeostasis (hence their name) via, among
others, effects on glycogen metabolism (for review see
McMahon et al. 1988). Although some direct effects of these
steroid hormones on glycogen metabolism have been de-
scribed, it is well recognized that they also act indirectly by
influencing cells’ responsiveness to other hormones
(Sapolsky et al. 2000). For example, it was demonstrated that,
in perfused liver of adrenalectomized rats, stimulation of
glycogenolysis by adrenaline and glucagon was reduced com-
pared to control animals (Exton et al. 1972).
GCs and sleep deprivation
GCs affect cerebral metabolism bymodulating glucose uptake
and utilization in cultured neurons and astrocytes (Allaman
et al. 2004; Horner et al. 1990; Landgraf et al. 1978; Virgin
et al. 1991). Adrenalectomy is followed by decreased glucose
levels and increased glycolytic intermediates in the cortex
(Plaschke et al. 1996). In most brain regions, GCs decrease
local cerebral glucose utilization, whereas adrenalectomy in-
creases it (e.g. see Doyle et al. 1994; Kadekaro et al. 1988).
GCs also affect brain glycogen stores. In cultured cortical and
hippocampal astrocytes, GCs decrease glycogen levels
(Allaman et al. 2004; Tombaugh et al. 1992). Similarly, adre-
nalectomy can either increase brain glycogen levels
(Passonneau et al. 1971) or have no effect in the whole brain
(Goldberg and O’Toole 1969) or in the cortex (Plaschke et al.
1996).
Because GCs influence brain glycogen levels and are in-
creased during SD, this raises the question of the contribution
of GCs to changes of glycogen levels observed during SD as
well as for their role in the homeostatic regulation of sleep. A
first observation suggesting a link between glycogen metabo-
lism and GCs during SD has been obtained by Heller and
collaborators (Franken et al. 2003). Using three inbred mice
strains, i.e. AK, D2, and B6, they showed that changes in brain
glycogen after SD are strongly influenced by brain region and
genotype (see above and Fig. 4). Although corticosterone
levels after SD were not measured in this work, it was sug-
gested that genotype differences in corticosterone induction
during SDmight contribute to the glycogen increase observed
in B6 mice and the decreases observed in AK and D2 mice,
based on studies showing a decreased corticosterone response
to stress in B6 mice (e.g. see Roberts et al. 1992; Ryabinin
et al. 1999).
Heller’s group investigated the influence of GC during SD
by measuring glycogen stores in different brain regions in
intact and adrenalectomized (with corticosterone replacement;
Adx) Long-Evans rats after 6 h of SD (Gip et al. 2004).
Following SD in control animals, glycogen levels de-
creased in the cerebellum and hippocampus but not in
the cortex or brainstem. In contrast, glycogen levels in
the cortex of Adx rats increased by 43 % after SD,
while other regions were unaffected. These results un-
equivocally demonstrate that in the absence of a GC
surge (prevented by adrenalectomy), glycogen stores in
all investigated brain regions were spared, implying a
direct effect of GCs on cerebral glycogen levels regula-
tion during SD. Moreover, this is in agreement with the
notion that elevated GCs secretion during SD causes
brain glycogenolysis and unbalances the synthesis/
degradation ratio.
In addition to changes of glucose metabolism, the effect of
adrenalectomy observed in Heller’s study on glycogen levels
may be explained by in vitro data that showing a suppressing
action of GC on the synthesis of glycogen induced by NA in
astrocytes (Allaman et al. 2004). In Allaman et al. (2004) it
was observed that exposure of primary cultures of cortical
astrocytes to dexamethasone (DEX), a synthetic GC, results in
the reduction of NA-induced glycogen resynthesis. DEX does
not act through alteration of signal transduction mechanisms,
as cAMP formation or PTG mRNA induced by noradrenergic
stimulation was unchanged. In this context, it would be of
interest to determine whether the suppressing action of GCs
on long-term glycogen regulation by NA is selective or also
effective for other neuromodulators such as VIP and Ade.
These observations also support the view that glycogen me-
tabolism during SD may be balanced between synthesis (e.g.
induced by NA and Ade) and degradation (induced by GCs
per se but also by the suppressive effects on NA-induced
glycogen synthesis) which may increase glycogen turnover.
Such view is strengthened by the observations that prolonged
wakefulness increases glycogen turnover in the cortex as
shown by a NMR study (see above) (Morgenthaler et al.
2009).
One should note that in the experiments by Heller’s and
collaborators on Adx Long-Evans rats, SD protocol induces a
massive increase in GCs in intact animals (at least 8 fold
increase) (Gip et al. 2004). For comparison, the GCs fold-
increase observed in AK and B6 mice are around 2 and 3,
respectively (8 for D2, which is similar to the value for Long-
Evans rats in Gip et al. 2004). Therefore, the high amplitude in
GCs surge during SD as observed in Long-Evans rats may
also amplify (override normal regulation) the GCs effects on
glycogen levels. Interestingly, and as mentioned above, Petit
et al (2010) compared the effects of wakefulness induced by
“gentle” SD and or following injection of the wakefulness-
promoting drug MOD on the expression of genes related to
glucose and glycogen metabolism, GS activity as well as on
glycogen levels in the cortex of the outbred mice strain OF1
(Petit et al. 2010). In this study plasma corticosterone were not
influenced byMOD whereas a moderate (2 fold) increase was
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observed following “gentle” SD. Despite this differential ef-
fect on GCs plasma levels, MOD and “gentle” SD exerted a
similar influence on gene expression including PTG, GS
activity and on glycogen levels. It could thus be concluded
that the mild stress induced by “gentle” SD was unlikely
involved in the effects of “gentle” SD on glycogen metabo-
lism indices analyzed including glycogen content at the corti-
cal level.
Are GCs modulators of sleep homeostasis?
An important question is therefore the role of GCs surge in the
homeostatic regulation of sleep. In human, plasma cortisol
(and corticosterone in rodents) concentration follows a circa-
dian rhythm independent of sleep. It peaks at the time of
awakening and slowly decreased during waking to reach a
minimum when sleep begins (Van Cauter et al. 1991). This
observation suggests a role of GCs in the building of sleep
pressure. Recently, Mongrain and collaborators provided an
important piece of work to answer this question (Mongrain
et al. 2010). In this study, they aimed to elucidate the contri-
bution of the corticosterone component of the stress response
to the sleep-wake associated changes in the electrophysiolog-
ical correlates of sleep need. To this end, they took advantage
of D2 mice which display high corticosterone increase fol-
lowing SD to determine the contribution of this high cortico-
sterone increase to blunted SWA rebound in Adx animals with
corticosterone replacement. These results clearly demonstrat-
ed that while Adx successfully abolished the SD–induced
increase in corticosterone secretion, Adx affected neither the
baseline dynamics of SWAnor the increase in SWA after sleep
deprivation as compared to in both intact controls and the
sham-lesioned mice. Importantly, quantity and distribution of
sleep, similarly to SWA during SWS, remain unaffected. The
fact that Adx does not influence the SWA response to SD,
argues against a major role of GCs in the homeostatic regula-
tion of sleep. More importantly, whatever are the effects of
GCs in SD in the regulation of glycogen levels, GCs do not
appear to participate in the homeostatic regulations of sleep as
shown by Mongrain’s work. Therefore, such results (modula-
tion or absence of modulation of glycogen levels by GCs as
observed in the different studies presented in this section) also
questioned the importance of glycogen store replenishment as
a regulator of sleep homeostasis.
Concluding remarks
During the last decade, efforts were made to validate or
invalidate the original hypothesis made by Benington and
Heller on the role played by glycogen metabolism in the
homeostatic regulation of sleep (part of these data have
already been reviewed by Scharf and collaborators (Scharf
et al. 2008)) . When considering results obtained in the differ-
ent studies reviewed here, one can conclude that, contrary to
what was initially postulated (i.e.glycogen reserves are mobi-
lized during wakefulness), cortical glycogen levels remain
relatively stable throughout the sleep-wake cycle, except at
the beginning of rest and active periods, where glycogen
levels rise and fall respectively for few minutes in response
to rapid change in neuronal activity. More striking, glycogen
reserves did not consistently decrease when wakefulness is
prolonged.
Most results rather support the notion that, during wake-
fulness, a parallel glycogen synthesis and degradation sets
resulting in a glycogen turnover increase. This is in accor-
dance with the “glycogenetic” hypothesis which postulates
the occurrence of a glycogen synthesis during waking. How-
ever, the assumption of the “glycogenetic” hypothesis that
glycogen synthesized during waking could favor sleep
(SWS and /or PS), was not verified in the experiments in
which glycogen mobilization was pharmacologically blocked
by DAB (Fig. 5), at least when it was acutely administrated.
Hence, none of the actual results (including GCs effect on
sleep homeostasis) fully support a direct correlation between
sleep and glycogen regulation (i.e. BHH or “glycogenetic”
hypothesis) (Fig. 3). Nevertheless, a link between glycogen
metabolism and sleep mechanisms could not be totally ex-
cluded. Indeed, experimental studies present several limita-
tions that may impede the establishment of a direct role of
glycogen metabolism in sleep regulation:
– Modulation (i.e. no change or increase) of glycogen
levels was mainly assessed in the cortex (or whole brain)
extracts of rodents whereas only few studies investigated
possible changes in glycogen level in other brain areas
such as cerebellum or brainstem. Interestingly, in these
latter two brain areas a different regulation of glycogen
content after SD was observed, suggesting that associa-
tion between sleep homeostasis and glycogen levels may
be stronger in these regions than in the cortex or whole
brain extracts. Therefore, studies focusing on different
and specialized brain structures might reveal important
link between glycogen metabolism and sleep. In particu-
lar, comparison of sleep-induced glycogen levels varia-
tion between sleep-promoting areas (preoptic area, basal
forebrain,…) and wake-promoting areas (posterior hypo-
thalamus, locus coeruleus area,…), which may be sup-
posed to display more pronounced variations during vig-
ilance states, may bring interesting information to address
this issue. Similarly, while glycogen-containing astro-
cytes can be found in both grey and white matters, only
one study specifically assessed glycogen levels changes
in white matter during SD (Kong et al. 2002). It was
observed that SD impacted glycogen levels in both white
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and grey matters equally, indicating that white matter
glycogen may also undergo specific regulation during
sleep which may deserve particular interest.
– Regulation of glycogen metabolism is likely better
reflected by turnover determinations rather than by static
measurements of glycogen levels, as indicated by the
work of Morgenthaler and collaborators using NMR
spectroscopy (Morgenthaler et al. 2009). Therefore, ef-
forts to establish associations between brain glycogen
turnover and sleep homeostasis would be of interest in
order to delineate the importance of glycogenmetabolism
in this process.
– It is classically assumed that SD is a stress per se, hence
unavoidably accompanying SD protocols. While GCs do
not constitute the only stress marker, an increase in GCs is
usually observed in classical SD procedures (even in
“gentle” sleep deprivation such as in most of the studies
reviewed here (Gip et al. 2004; Petit et al. 2010)). Since,
GCs affect glycogen regulation by dampening its synthe-
sis, GCs have to be considered as a confounding factor in
SD protocols. Fortunately, there are means to circumvent
the GCs issue. For instance, pharmacological SD as used
by Petit and co-workers illustrates such a possible way to
avoid increase in plasma GCs (Petit et al. 2010). More-
over, the development of new non-stressful SD devices
represents another interesting alternative way to prevent
stress effects in metabolism-sleep interactions studies
(e.g. see Leenaars et al. 2011; Petit et al. 2013).
– Mechanisms of glycogen regulation based on the
“glycogenetic hypothesis” are supported by results ob-
tained for 6 h SD. When wakefulness is more prolonged
(such as in 12 h of SD), glycogen depletion is observed
(Kong et al. 2002), suggesting that other mechanisms of
glycogen regulation take place.
To conclude, we should underline that thanks to the initial
BHH, several experiments have been performed and contrib-
uted to test it which have contributed a better understanding,
albeit incomplete, of the relationship between glycogen regu-
lation and sleep homeostasis. Even if the Benington and
Heller’s assumption that sleep serves for glycogen replenish-
ment is not supported by the experimental data, their hypoth-
esis underlined the important role of astrocytic energy metab-
olism in sleep regulation. Quite recently, such a role of astro-
cytes related to Ade has been uncovered. For instance, Halassa
and co-workers reported the loss of SWA rebound after SD in
mice in which the vesicular release of ATP, the precursor of
Ade, was suppressed specifically in astrocytes (Frank 2013;
Halassa et al. 2009). In fact, a body of evidence indicates that
astrocytes-released ATP modulates neuronal transmission by
acting on A1 receptors which ultimately leads to a SWA
increase (Blutstein and Haydon 2013). Interestingly, ATP
release evoked by glutamate, potassium and adenosine in
cultured astrocytes was shown to be prevented by DAB (Hertz
et al. 2014), providing a possible yet unsuspected link be-
tween glycogen metabolism, ATP release and sleep regula-
tion. In line with the importance of astrocytes in higher brain
functions, the involvement of glycogen metabolism in mem-
ory processes has recently been unveiled in rodents (Newman
et al. 2011; Suzuki et al. 2011).
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